SAN CARLOS, Calif.--(BUSINESS WIRE)--BioTrace Medical, Inc., today announced the company’s key activities at the 2017 Transcatheter Valve Technologies (TVT) conference, which will take place June 14-17 at the Sheraton Grand Chicago.
BioTrace Medical’s Tempo Temporary Pacing Lead is designed for secure and stable cardiac pacing with the goal of reducing complications and allowing patients to ambulate sooner after procedures such as transcatheter valve aortic replacement (TAVR) procedures. Cleared by the Food and Drug Administration (FDA) in October 2016, it is the only active fixation temporary pacing lead available in the U.S. The Tempo Lead features a novel active fixation mechanism, bipolar electrodes and a soft tip. This unique design mitigates the risks of dislodgement and perforation. The Lead ensures stability during rapid pacing and facilitates patient ambulation post-procedure, which can lead to a reduced length of hospital stay.
The Tempo Lead will be featured in the following presentations and events at TVT 2017:
Oral Presentation:
Thursday, June 15
New Technology
Forum: TAVR I – Ballroom X
11:10 AM CT: “Advances in
Temporary Transvenous Pacemakers: The BioTrace Tempo Lead”
Presenter:
Tamim Nazif, M.D., Director of Clinical Services, Structural Heart &
Valve Center, Columbia University Medical Center
Live Cases:
Friday, June 16
TAVR Day II – Ballroom
IV-VII
2:00 PM CT: Session I: Live Case #9
4:30 PM CT:
Session III. Live Case #11
New York Presbyterian/Columbia
University Medical Center
Operators: Isaac George, M.D.; Rebecca T.
Hahn, M.D.; Susheel Kodali, M.D.; Tamim Nazif, M.D.; Torsten P. Vahl,
M.D.
About BioTrace Medical
BioTrace Medical, Inc., a private venture backed company based in San Carlos, Calif., is dedicated to reinventing temporary pacing to improve patient outcomes and reduce hospital costs. For more information, visit www.biotracemedical.com.
